SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD), an incurable neurodegenerative disorder, has a complex pathogenesis including protein aggregation and the dysregulation of neuronal transcription and metabolism. Here, we demonstrate that inhibition of sirtuin 2 (SIRT2) achieves neuroprotection in cellular and invertebrate models of HD. Genetic or pharmacologic inhibition of SIRT2 in a striatal neuron model of HD resulted in gene expression changes including significant down-regulation of RNAs responsible for sterol biosynthesis. Whereas mutant huntingtin fragments increased sterols in neuronal cells, SIRT2 inhibition reduced sterol levels via decreased nuclear trafficking of SREBP-2. Importantly, manipulation of sterol biosynthesis at the transcriptional level mimicked SIRT2 inhibition, demonstrating that the metabolic effects of SIRT2 inhibition are sufficient to diminish mutant huntingtin toxicity. These data identify SIRT2 inhibition as a promising avenue for HD therapy and elucidate a unique mechanism of SIRT2-inhibitor-mediated neuroprotection. Furthermore, the ascertainment of SIRT2’s role in regulating cellular metabolism demonstrates a central function shared with other sirtuin proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accordingly, SIRT2 inhibition or its genetic deletion has provided beneficial effects in different mouse models of Huntington's disease (Chopra et al., 2012;Luthi-Carter et al., 2010), Parkinson's disease (de Oliveira et al., 2017;Esteves et al., 2019;Sun et al., 2018); and Alzheimer's disease (AD) (Bai et al., 2022;Sola-Sevilla et al., 2023;Biella et al., 2016;Wang et al., 2020).”
From Microglial SIRT2 deficiency aggravates cognitive decline and amyloid pathology in Alzheimer’s disease (2025) · cites this paper as Luthi-Carter et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Self-citationThe Human Sir2 Ortholog, SIRT2, Is an NAD+-Dependent Tubulin Deacetylase
North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M., & Verdin, E. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00038-8 · Cited by 1,536
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228
Self-citationSirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease
Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., Volk, C. B., Maxwell, M. M., Rochet, J.-C., McLean, P. J., et al. (2007) · Science · doi:10.1126/science.1143780 · Cited by 1,062
Self-citationFassbender, K., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081620098 · Cited by 860
Dompierre, J. P., Godin, J. D., Charrin, B. C., Cordelières, F. P., King, S. J., Humbert, S., & Saudou, F. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0037-07.2007 · Cited by 792
HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin.
Iwata, A., Riley, B. E., Johnston, J. A., & Kopito, R. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508786200 · Cited by 719 · cited 1×
“For example, increasing α-tubulin acetylation could ameliorate HD pathogenesis by independent mechanisms such as regulating mutant Htt aggregation or degradation (39) or the transport of membranous vesicles, including those containing BDNF (40).”
BackgroundFerrante, R. J., Kubilus, J. K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi-Carter, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-28-09418.2003 · Cited by 693
Self-citationSirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis
Vaquero, A., Scher, M. B., Lee, D. H., Sutton, A., Cheng, H.-L., Alt, F. W., Serrano, L., Sternglanz, R., & Reinberg, D. (2006) · Genes & Development · doi:10.1101/gad.1412706 · Cited by 665
SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction
Wang, F., Nguyen, M., Qin, F. X., & Tong, Q. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00304.x · Cited by 655
Neurological abnormalities in a knock-in mouse model of Huntington's disease
Lin, C.-H. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.137 · Cited by 592
Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons
Parker, J. A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H., & Néri, C. (2005) · Nature Genetics · doi:10.1038/ng1534 · Cited by 512
Self-citationSIRT2 Regulates Adipocyte Differentiation through FoxO1 Acetylation/Deacetylation
Jing, E., Gesta, S., & Kahn, C. R. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.07.003 · Cited by 487
Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration
Kaltenbach, L. S., Romero, E., Becklin, R. R., Chettier, R., Bell, R., Phansalkar, A., Strand, A., Torcassi, C., Savage, J., Hurlburt, A., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030082 · Cited by 434
Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., & Russell, D. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303415200 · Cited by 421 · cited 1×
“In fact, CYP46A1 has been deemed amaster regulator of neuronal cholesterol biosynthesis based on the evidence that 24-OH-cholesterol has a more significant role than the SREBP cleavage-activating proteins (SCAPs 1 and 2) in regulating the nuclear translocation of SREBP-2 in this cell type (37, 38).”
BackgroundInterphase Nucleo-Cytoplasmic Shuttling and Localization of SIRT2 during Mitosis
North, B. J., & Verdin, E. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000784 · Cited by 325
Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease
Valenza, M., Rigamonti, D., Goffredo, D., Zuccato, C., Fenu, S., Jamot, L., Strand, A., Tarditi, A., Woodman, B., Racchi, M., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3355-05.2005 · Cited by 298 · cited 2×
“(22, 24, 26, 27), and a direct (albeit weak) interaction with SREBP2 (28).”
BackgroundSelf-citationPallos, J., Bodai, L., Lukacsovich, T., Purcell, J. M., Steffan, J. S., Thompson, L. M., & Marsh, J. L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn273 · Cited by 265
Self-citationLi, W., Zhang, B., Tang, J., Cao, Q., Wu, Y., Wu, C., Guo, J., Ling, E.-A., & Liang, F. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4181-06.2007 · Cited by 265
Proteolipid Protein Is Required for Transport of Sirtuin 2 into CNS Myelin
Werner, H. B., Kuhlmann, K., Shen, S., Uecker, M., Schardt, A., Dimova, K., Orfaniotou, F., Dhaunchak, A., Brinkmann, B. G., Möbius, W., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1254-07.2007 · Cited by 259
Benn, C. L., Sun, T., Sadri-Vakili, G., McFarland, K. N., DiRocco, D. P., Yohrling, G. J., Clark, T. W., Bouzou, B., & Cha, J.-H. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2126-08.2008 · Cited by 205
Apostol, B. L., Kazantsev, A., Raffioni, S., Illes, K., Pallos, J., Bodai, L., Slepko, N., Bear, J. E., Gertler, F. B., Hersch, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2628045100 · Cited by 173
Self-citationStatins reduce neuronal α‐synuclein aggregation in in vitro models of Parkinson’s disease
Bar‐On, P., Crews, L., Koob, A. O., Mizuno, H., Adame, A., Spencer, B., & Masliah, E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05254.x · Cited by 166
Biological and Potential Therapeutic Roles of Sirtuin Deacetylases
Taylor, D. M., Maxwell, M. M., Luthi‐Carter, R., & Kazantsev, A. G. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8357-y · Cited by 162
Self-citationFernández, A., Llacuna, L., Fernández-Checa, J. C., & Colell, A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4909-08.2009 · Cited by 153
Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease
Leoni, V., Mariotti, C., Tabrizi, S. J., Valenza, M., Wild, E. J., Henley, S. M. D., Hobbs, N. Z., Mandelli, M. L., Grisoli, M., Björkhem, I., et al. (2008) · Brain · doi:10.1093/brain/awn212 · Cited by 145
Microtubule Deacetylases, SirT2 and HDAC6, in the Nervous System
Southwood, C. M., Peppi, M., Dryden, S. C., Tainsky, M. A., & Gow, A. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9127-6 · Cited by 144
Karasinska, J. M., Rinninger, F., Lütjohann, D., Ruddle, P., Franciosi, S., Kruit, J. K., Singaraja, R. R., Hirsch-Reinshagen, V., Fan, J., Brunham, L. R., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4741-08.2009 · Cited by 133
Cholesterol in Alzheimers Disease: Unresolved Questions
Stefani, M., & Liguri, G. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313899 · Cited by 133
Trushina, E., Singh, R. D., Dyer, R. B., Cao, S., Shah, V. H., Parton, R. G., Pagano, R. E., & McMurray, C. T. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl434 · Cited by 122
Valenza, M., Leoni, V., Tarditi, A., Mariotti, C., Björkhem, I., Di Donato, S., & Cattaneo, E. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.004 · Cited by 115
Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation
Valenza, M., Carroll, J. B., Leoni, V., Bertram, L. N., Bjorkhem, I., Singaraja, R. R., Di Donato, S., Lutjohann, D., Hayden, M. R., & Cattaneo, E. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm170 · Cited by 115
Brain neutral lipids mass is increased in α‐synuclein gene‐ablated mice
Barceló‐Coblijn, G., Golovko, M. Y., Weinhofer, I., Berger, J., & Murphy, E. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04348.x · Cited by 107
Runne, H., Régulier, E., Kuhn, A., Zala, D., Gokce, O., Perrin, V., Sick, B., Aebischer, P., Déglon, N., & Luthi-Carter, R. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3044-08.2008 · Cited by 96
Self-citationWang, Y., Muneton, S., Sjövall, J., Jovanovic, J. N., & Griffiths, W. J. (2008) · Journal of Proteome Research · doi:10.1021/pr7006076 · Cited by 81
Halford, R. W., & Russell, D. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813349106 · Cited by 75 · cited 1×
“Whereas increased activity of cholesterol biosynthetic enzymes and cholesterol accumulation generally occurs during aging, lower cholesterol levels have been associated with peripheral and central benefits, including increased lifespan and decreased amyloid accumulation (41, 42).”
BackgroundCyp46-mediated cholesterol loss promotes survival in stressed hippocampal neurons
Martín, M. G., Trovò, L., Perga, S., Sadowska, A., Rasola, A., Chiara, F., & Dotti, C. G. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.022 · Cited by 43
Molecular consequences of altered neuronal cholesterol biosynthesis
Korade, Ž., Kenworthy, A. K., & Mirnics, K. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21917 · Cited by 42
Drug targeting of dysregulated transcription in Huntington's disease
Kazantsev, A. G., & Hersch, S. M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.02.005 · Cited by 36
Self-citationRudinskiy, N., Kaneko, Y. A., Beesen, A. A., Gökçe, Ö., Régulier, E., Déglon, N., & Luthi‐Carter, R. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06344.x · Cited by 34
Self-citationHuntington's and other polyglutamine diseases: many effects of single gene mutations
Luthi‐Carter, R. (2007) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2007.10.002 · Cited by 15
Self-citation
Cited by
The sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
SIRT1 and SIRT2: emerging targets in neurodegeneration
Donmez, G., & Outeiro, T. F. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302451 · Cited by 411
Seven sirtuins for seven deadly diseases ofaging
Morris, B. J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.525 · Cited by 377
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
Walker, A. K., Yang, F., Jiang, K., Ji, J.-Y., Watts, J. L., Purushotham, A., Boss, O., Hirsch, M. L., Ribich, S., Smith, J. J., et al. (2010) · Genes & Development · doi:10.1101/gad.1901210 · Cited by 357
“The regulation of SREBP proteins by other sirtuin family members has been demonstrated recently in a neurodegeneration model (Luthi-Carter et al. 2010).”
Background
Metadata
- Authors
- Luthi-Carter, R., Taylor, D. M., Pallos, J., Lambert, E., Amore, A., Parker, A., Moffitt, H., Smith, D. L., Runne, H., Gokce, O., Kuhn, A., Xiang, Z., Maxwell, M. M., Reeves, S. A., Bates, G. P., Neri, C., Thompson, L. M., Marsh, J. L., & Kazantsev, A. G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-04-08
- Volume
- 107
- Issue
- 17
- Pages
- 7927-7932
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2069423751
- Cited by
- 336
- References
- 42
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.